Balaglitazone|cas 199113-98-9|DC Chemicals

Balaglitazone|cas 199113-98-9|DC Chemicals

Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.

IC50 Value:

Target: PPARγ

in vitro: The Rs for the separations were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone.

Product Name: Balaglitazone|Cat No: DC9602|Cas: 199113-98-9|Molecule Formular: C20H17N3O4S|Molecule Weight: 395.4317|Other names: Balaglitazone.

Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-γ.
in vitro: The Rs for the separations were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone. The squared correlation coefficients (r2) were found to be 0.999 for all three compounds.
in vivo: Balaglitazone treated groups shown significantly reduce of HbA1c (%), FSG (mmol/L), postprandial glucose as comparison to pioglitazone. Balaglitazone 10 mg and 20 mg show the similar magnitudes of the effects which comparable to the effects seen in the pioglitazone 45 mg group. The incidence of fluid retention and fat accumulation fewer than those observed with pioglitazone 45 mg. Sixty male dio induced obese rats were divided into five categories: vehicle, pioglitazone 10 mg/kg, pioglitazone 30 mg/kg, balaglitazone 5 mg/kg, balaglitazone 10 mg/kg. At day -7, 21 and 42 fasting serum samples were collected and whole body tissue composition was evaluated by MR scanning.

For research only, not for human use!